FINWIRES · TerminalLIVE
FINWIRES

Gold Rises as the Dollar and Yields Fall After a Report Showed U.S. Inflation Continues to Run Hot

作者

-- Gold rose early Thursday as the dollar dropped after a report showed a key U.S. inflation measure rose last month while first-quarter gross domestic product rose less than expected.

Gold for June delivery was last seen up $85.70 to US$4,647.20 per ounce, remaining within the US$200 range it has traded within for the past month.

The U.S. Bureau of Economic Analysis reported the March Personal Consumption Expenditures (PCE) Index, the Federal Reserve's preferred inflation measure, rose 0.7% in March from the prior month, up from 0.4% fin February, but matching expectations according to Marketwatch. Core PCE, excluding volatile food and energy, rose 3.2% annualized, up from 3.0% in February and again matching expectations.

The bureau also issued its first estimate of first-quarter U.S. GDP growth, reporting the measure rose at a 2.0% pace, up from 0.5% in the prior quarter and under expectations for a 2.2% rise.

Gold's gain comes despite expectations higher interest rates are on the way as the war on Iran pushes up inflation. The Federal Reserve's policy committee on Wednesday ended its two-day meeting on Wednesday leaving rates unchanged, but signaled hikes may be on the horizon as inflation climbs.

"Gold has attracted fresh demand despite rising bond yields and a firmer dollar following Wednesday's FOMC meeting, where rates were left unchanged, but several members signalled a desire to remove the easing bias as the Iran war continues to cloud the economic outlook," Saxo Bank wrote.

Still, the dollar was sharply lower early following the economic data, with the ICE dollar index last seen down 0.5 points to 98.46. Treasury yields also fell, with the yield on the U.S. two-year note last seen down 6.5 basis points to 3.9%, while the 10-year note was paying 4.39%, down 4.4 points.

相關文章

Sectors

產業動態:消費者

週四下午,消費性股票走高,道富消費必需品精選行業SPDR ETF (XLP)上漲1.4%,道富非必需消費品精選行業SPDR ETF (XLY)上漲0.4%。 公司方面,蘭姆韋斯頓(LW)股價上漲1.6%,此前股東Starboard Value週四致信董事會,表示公司應召開投資者日活動,並將盈利預期調整至正常水平。

$LW
Research

研究快訊:CFRA維持對Firstenergy Corp.股票的買進評等。

獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點摘要如下:我們將12個月目標股價下調1美元至55美元,本益比為20倍,基於未來12個月每股收益預期2.75美元,高於五年平均15.6倍。我們將2026年每股收益預期下修0.02美元至2.72美元,並將2027年每股收益預期下修0.01美元至2.93美元。第一季核心每股收益年增7.5%,打破了先前連續三個季度下滑的局面,我們預計在整個預測期內,成長動能將持續。 我們觀察到資料中心需求呈現正面趨勢,長期合約需求(4.3 GW)自 2026 年 2 月(4.1 GW)以來成長了 4%,自 2025 年 2 月(2.9 GW)以來成長了 47%;同時,在建專案需求(14.9 GW)自 2026 年 2012 年 125%, 2 月(6.1 GW)以來增長了一倍以上。自 2022 年以來,FE 已將基礎維運成本降低了 2 億美元以上(15%),預計 2026 年第一季將年比進一步下降約 5%,同時可靠性指標也得到提升。我們認為,FE 的成本控制、服務品質的提升以及具有競爭力的價格定位,將轉化為更有利的費率調整結果、更低的拒付風險以及更高的潛在淨資產收益率 (ROE)。

$FE
Australia

市場動態:FDA專家小組投票反對阿斯特捷利康乳癌藥物的益處

根據彭博社週四報道,美國食品藥物管理局(FDA)腫瘤藥物諮詢委員會否決了阿斯特捷利康(AZN)用於治療乳癌的候選藥物卡美司群(Camizestrant)的療效。 彭博社稱,六名委員會成員投票反對該藥物,因為他們對試驗設計及其在臨床應用中的潛在影響存在分歧。 根據一份簡報文件,該藥物試驗達到了無惡化存活期(PFS)的主要終點以及無惡化存活期2(PFS2)終點,但FDA認為PFS2不適合作為監管決策的終點。 (市場動態新聞來自與全球市場專業人士的對話。這些資訊據信來自可靠來源,但可能包含傳聞和推測。準確性無法保證。)Price: $189.60, Change: $+4.40, Percent Change: +2.37%

$AZN